We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
-1.57%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$6.49B
AUM Growth
-$396M
(-5.7%)
Cap. Flow
-$220M
Cap. Flow
% of AUM
-3.39%
Top 10 Holdings %
Top 10 Hldgs %
43.16%
Holding
163
New
23
Increased
16
Reduced
43
Closed
16
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
LIAN
LianBio American Depositary Shares
LIAN
|
+$643M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
+$97.4M |
| 3 |
BLU
BELLUS Health Inc.
BLU
|
+$50.7M |
| 4 |
ISO
IsoPlexis Corporation Common Stock
ISO
|
+$45.4M |
| 5 |
Zentalis Pharmaceuticals
ZNTL
|
+$33.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Atea Pharmaceuticals
AVIR
|
+$79.2M |
| 2 |
NVTA
Invitae Corporation
NVTA
|
+$50.6M |
| 3 |
Beam Therapeutics
BEAM
|
+$46.8M |
| 4 |
DBVT
DBV Technologies
DBVT
|
+$37.7M |
| 5 |
Iovance Biotherapeutics
IOVA
|
+$30M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 85.98% |
| 2 | Miscellaneous | 13.04% |
| 3 | Financials | 0.8% |
| 4 | Industrials | 0.09% |
| 5 | Consumer Staples | 0.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Regenxbio
RGNX
$525M
| – | – |
-89,283
| Closed | -$3.74M |
|
|
RNAM
152
DELISTED
Avidity Biosciences
RNAM
| – | – |
-885,818
| Closed | -$21.8M |
|
153
Taysha Gene Therapies
TSHA
$1.65B
| – | – |
-320,440
| Closed | -$5.97M |
|
|
PSTX
154
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| – | – |
-787,745
| Closed | -$5.74M |
|
|
IMGO
155
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
| – | – |
-125,000
| Closed | -$2.5M |
|
|
CCXI
156
CALL
DELISTED
ChemoCentryx, Inc.
CCXI
| – | – |
-923,200
| Closed | -$15.8M |
|
|
HCAQ
157
DELISTED
HealthCor Catalio Acquisition Corp. Class A Ordinary Shares
HCAQ
| – | – |
-1,500,000
| Closed | -$14.8M |
|
|
CMLTU
158
DELISTED
CM Life Sciences III Inc. Unit
CMLTU
| – | – |
-1,250,000
| Closed | -$12.8M |
|
Similar funds
QP
FCBT
RWM
AWA
WHRC
KGA
LSERS
CAG
Perceptive Advisors's Q4 2021 Portfolio in Review
As of Q4 2021, Perceptive Advisors held 163 positions worth $6.49B, down 5.7% from $6.88B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Perceptive Advisors withdrew a net $220M in Q4 2021, closing 16 positions and reducing 43 holdings. Its most notable exit was Atea Pharmaceuticals, an estimated $79.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 86% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Perceptive Advisors opened a new position in LianBio American Depositary Shares worth $347M.
- Perceptive Advisors's largest Q4 2021 buy was LianBio American Depositary Shares: 56,319,960 shares worth $347M.
- Perceptive Advisors added most to Apellis Pharmaceuticals in Q4 2021, an estimated $32.9M increase.
- Perceptive Advisors's biggest Q4 2021 reduction was Invitae Corporation, cutting an estimated $50.6M.
- Perceptive Advisors fully exited Atea Pharmaceuticals in Q4 2021, selling an estimated $79.2M.
- Perceptive Advisors's ten largest holdings make up 43% of its $6.49B portfolio in Q4 2021.
- Perceptive Advisors opened 23 new positions and closed 16 in Q4 2021.
- Perceptive Advisors's portfolio value fell 5.7% quarter-over-quarter to $6.49B.
Based on Perceptive Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.